ERBB2 and breast carcinoma: Therefore, the aim of this study was to identify risk factors for trastuzumab-induced cardiotoxicity in patients with early-stage HER2 positive breast cancer, with an emphasis on the HER2 Ile655Val polymorphism, and describe the characteristics of trastuzumab cardiotoxicity.